The U.S. Department of Health and Human Services (HHS) has announced new details of its agreement with Regeneron to extend its public-private partnership to develop monoclonal antibodies for COVID-19 strains and variants.
The modification to Regeneron’s contract with the Administration for Strategic Preparedness and Response’s (ASPR’s) Biomedical Advanced Research and Development Authority (BARDA), is valued at $326M and supports Project NextGen.
Project NextGen, a $5 billion initiative led by BARDA in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), coordinates across the federal government and the private sector to advance innovative vaccines and therapeutics into clinical trials, regulatory review, and potential commercial availability for the American people. The project builds on a better understanding of COVID-19 – with HHS developing, using, and constantly re-evaluating the strengths and weaknesses of current vaccines and therapeutics for over three years.
This new agreement included a clause where Regeneron committed that if a product is commercialized, its list price in the United States will be equal to or less than its retail price in comparable markets globally. Inclusion of this clause is the result of HHS’s and Regeneron’s shared interest in ensuring enduring and equitable access to therapeutics developed under public-private partnerships for all Americans.